{"id":"W2791520417","doi":"10.1200/jco.2018.36.6_suppl.tps383","title":"ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Androgen deprivation therapy; Internal medicine; Oncology; Abiraterone acetate; Enzalutamide; Clinical endpoint; Placebo; Performance status; Androgen receptor; Cancer; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001129378,0.001383803,0.001184143,0.0005316417,0.000351861,0.0007051075,0.0008958443,0.00112941,0.007811035],"category_scores_gemma":[0.0006299543,0.0004362155,0.001722224,0.0004235666,0.0007509227,0.0006577508,0.0003471895,0.002442193,0.001202558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008235152,"about_ca_system_score_gemma":0.00173558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001412472,"about_ca_topic_score_gemma":0.005481767,"domain_scores_codex":[0.9997192,0.0001386233,0.00001155349,0.00003648082,0.00003434578,0.00005974766],"domain_scores_gemma":[0.9996368,0.00004552215,0.00008984987,0.0000207245,0.00002560658,0.000181463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7564284,0.03732076,0.004665963,0.002356586,0.002228281,0.0003339422,0.0002748204,0.002941515,0.02222835,0.0007188779,0.01356179,0.1569408],"study_design_scores_gemma":[0.7955402,0.1915562,0.005608224,0.00008133717,0.0003650872,0.0002543869,0.00004880619,0.0007929608,0.001124231,0.0003028931,0.004296824,0.0000288245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9715748,0.007777161,0.0006417862,0.001525382,0.0004399249,0.006821726,0.003773991,0.0004593595,0.006985867],"genre_scores_gemma":[0.9731538,0.004865471,0.002594466,0.002232142,0.0002333586,0.004863077,0.005203438,0.00005861016,0.00679558],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007811035,"threshold_uncertainty_score":0.02613056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1433848701866493,"score_gpt":0.5219258120212307,"score_spread":0.3785409418345814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}